TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
TherapeuticsMD (TXMD) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 Product Revenue Guidance
February 20, 2020 7:11 AM ESTTherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $15.9 million versus the consensus estimate of $12.83 million.
4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Companys Financial Guidance Full-Year... More